|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | XS0601 REDUCES THE INCIDENCE OF RESTENOSIS: A PROSPECTIVE STUDY OF 335 PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN CHINA显示文摘Background XS0601, consisting of active ingredients (Chuangxiongol and paeoniflorin), has been shown to inhibit arterial neointimal hyperplasia in animal models and in preliminary human studies. The objective of this study was to evaluate the safety and efficacy of XS0601 in preventing restenosis following percutaneous coronary intervention (PCI). Methods A multi-center, randomized, double-blind, placebo-controlled trial was conducted. A total of 335 patients were randomized into treatment with the oral administration of XS0601, or a placebo for 6 months after successful PCI. Angiographic follow-up was scheduled at 6 months, and clinical follow-ups performed at 1, 3 and 6 months after PCI. The primary end point was angiographic restenosis. The secondary end points were the combined incidence of death, target lesion nonfatal myocardial infarction, repeat angioplasty, and coronary artery bypass graft surgery. Results A total of 308 patients (91.9%) completed the study and 145 cases (47.1%) received angiographic follow-up. The restenosis rates were significantly reduced in the XS0601 group as compared with the placebo group (26.0% vs. 47.2%, P < 0.05), and the minimum lumen diameter (MLD) was greater [(2.08 ± 0.89) mm for XS0601 vs. (1.73 ± 0.94) mm for placebo, P < 0.05]. XS0601 also significantly reduced the combined incidence of major adverse cardiac event (10.4% in the XS0601 group vs. 22.7% in the placebo group, P < 0.05). The incidence of recurrent angina at 3 and 6 months after PCI was also significantly reduced in XS0601 group (7.1% and 11.0%) as compared with those in placebo group (19.5% and 42.9%) (P < 0.05). No significant side effects occurred within the 6-month follow-up period in the XS0601 group. Conclusion Administration of XS0601 for 6 months is demonstrated to be safe and effective in reducing restenosis in post-PCI patients. | CHEN Ke-ji SHI Da-zhuo XU Hao LUE Shu-zheng LI Tian-chang KE Yuan-nan ZHANG Min-zhou LU Xiao-yan SUN Rui-yuan YOU Shi-jie | 2006 | Chinese Medical Journal2006，，1： | 83 |
| 2 | Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases显示文摘在各种各样的纸巾的 microRNAs (miRNAs ) 的 Dysregulated 表示与许多疾病被联系了,包括癌症。这里,我们证明 miRNAs 在象老鼠,老鼠,牛的胎儿,小牛,和马那样的人和另外的动物的浆液和血浆是在场的。在浆液的 miRNAs 的层次在一样的种类的个人之中稳定、可再现、一致。采用 Solexa,我们定序健康中国题目的所有浆液 miRNAs 并且分别地在男、女的题目发现超过 100 和 91 浆液 miRNAs。我们也为肺癌症, colorectal 癌症,和糖尿病识别了浆液 miRNAs 的特定的表示模式,提供证据那浆液 miRNAs 为各种各样的疾病包含指纹。癌症特定的浆液 miRNAs 由 Solexa 获得了的二个非小的房间肺进一步在 75 个健康施主和 152 个癌症病人的独立审判被验证,用量的反向的抄写聚合酶链反应试金。通过这些分析,我们断定浆液 miRNAs 能为各种各样的癌症和另外的疾病的察觉用作潜在的 biomarkers。 | Xi Chen Yi Ba Lijia Ma Xing Cai Yuan Yin Kehui Wang Jig ang Guo Yujing Zhang Jiangning Chen Xing Guo Qibin Li Xiaoying Li Wenjing Wang Yan Zhang Jin Wang Xueyuan Jiang Yang Xiang Chen Xu Pingping Zheng Juanbin Zhang Ruiqiang Li Hongjie Zhang Xiaobin Shang Ting Gong Guang Ning Jun Wang Ke Zen Junfeng Zhang Chen-Yu Zhang | 2008 | Cell Research2008，18，10： | 975 |
| 3 | Exogenous plant MIR168a specifically targets mammalian LDLRAPI: evidence of cross-kingdom regulation by microRNA显示文摘 | Lin Zhang Dongxia Hou Xi Chen Donghai Li Lingyun Zhu Yuj ing Zhang Jing Li Zhen Bian Xiangying Liang Xing Cai Yuan Yin Cheng Wang Tianfu Zhang Dihan Zhu Dianmu Zhang Jie Xu Qun Chen Yi Ba Jing Liu Qiang Wang Jianqun Chen Jin Wang Meng Wang Qipeng Zhang Junfeng Zhang Ke Zen Chen-Yu Zhang | 2012 | Cell Research2012，22，1： | 155 |
| 4 | Future Physics Programme of BESⅢ显示文摘There has recently been a dramatic renewal of interest in hadron spectroscopy and charm physics. This renaissance has been driven in part by the discovery of a plethora of charmonium-like XYZ states at BESⅢ and B factories, and the observation of an intriguing proton-antiproton threshold enhancement and the possibly related X(1835) meson state at BESⅢ, as well as the threshold measurements of charm mesons and charm baryons. We present a detailed survey of the important topics in tau-charm physics and hadron physics that can be further explored at BESⅢ during the remaining operation period of BEPCⅡ. This survey will help in the optimization of the data-taking plan over the coming years, and provides physics motivation for the possible upgrade of BEPCⅡ to higher luminosity. | M.Ablikim M.N.Achasov P.Adlarson S.Ahmed M.Albrecht M.Alekseev A.Amoroso F.F.An Q.An Y.Bai O.Bakina R.Baldini Ferroli Y.Ban K.Begzsuren J.V.Bennett N.Berger M.Bertani D.Bettoni F.Bianchi J Biernat J.Bloms I.Boyko R.A.Briere L.Calibbi H.Cai X.Cai A.Calcaterra G.F.Cao N.Cao S.A.Cetin J.Chai J.F.Chang W.L.Chang J.Charles G.Chelkov Chen G.Chen H.S.Chen J.C.Chen M.L.Chen S.J.Chen Y.B.Chen H.Y.Cheng W.Cheng G.Cibinetto F.Cossio X.F.Cui H.L.Dai J.P.Dai X.C.Dai A.Dbeyssi D.Dedovich Z.Y.Deng A.Denig Denysenko M.Destefanis S.Descotes-Genon F.De Mori Y.Ding C.Dong J.Dong L.Y.Dong M.Y.Dong Z.L.Dou S.X.Du S.I.Eidelman J.Z.Fan J.Fang S.S.Fang Y.Fang R.Farinelli L.Fava F.Feldbauer G.Felici C.Q.Feng M.Fritsch C.D.Fu Y.Fu Q.Gao X.L.Gao Y.Gao Y.Gao Y.G.Gao Z.Gao B.Garillon I.Garzia E.M.Gersabeck A.Gilman K.Goetzen L.Gong W.X.Gong W.Gradl M.Greco L.M.Gu M.H.Gu Y.T.Gu A.Q.Guo F.K.Guo L.B.Guo R.P.Guo Y.P.Guo A.Guskov S.Han X.Q.Hao F.A.Harris K.L.He F.H.Heinsius T.Held Y.K.Heng Y.R.Hou Z.L.Hou H.M.Hu J.F.Hu T.Hu Y.Hu G.S.Huang J.S.Huang X.T.Huang X.Z.Huang Z.L.Huang N.Huesken T.Hussain W.Ikegami Andersson W.Imoehl M.Irshad Q.Ji Q.P.Ji X.B.Ji X.L.Ji H.L.Jiang X.S.Jiang X.Y.Jiang J.B.Jiao Z.Jiao D.P.Jin S.Jin Y.Jin T.Johansson N.Kalantar-Nayestanaki X.S.Kang R.Kappert M.Kavatsyuk B.C.Ke I.K.Keshk T.Khan A.Khoukaz P.Kiese R.Kiuchi R.Kliemt L.Koch O.B.Kolcu B.Kopf M.Kuemmel M.Kuessner A.Kupsc M.Kurth M.G.Kurth W.Kuhn J.S.Lange P.Larin L.Lavezzi H.Leithoff T.Lenz C.Li Cheng Li D.M.Li F.Li F.Y.Li G.Li H.B.Li H.J.Li J.C.Li J.W.Li Ke Li L.K.Li Lei Li P.L.Li P.R.Li Q.Y.Li W.D.Li W.G.Li X.H.Li X.L.Li X.N.Li X.Q.Li Z.B.Li H.Liang H.Liang Y.F.Liang Y.T.Liang G.R.Liao L.Z.Liao J.Libby C.X.Lin D.X.Lin Y.J.Lin B.Liu B.J.Liu C.X.Liu D.Liu D.Y.Liu F.H.Liu Fang Liu Feng Liu H.B.Liu H.M.Liu Huanhuan Liu Huihui Liu J.B.Liu J.Y.Liu K.Y.Liu Ke Liu Q.Liu S.B.Liu T.Liu X.Liu X.Y.Liu Y.B.Liu Z.A.Liu Zhiqing Liu Y.F.Long X.C.Lou H.J.Lu J.D.Lu J.G.Lu Y.Lu Y.P.Lu C.L.Luo M.X.Luo P.W.Luo T.Luo X.L.Luo S.Lusso X.R.Lyu F.C.Ma H.L.Ma L.L.Ma M.M.Ma Q.M.Ma X.N.Ma X.X.Ma X.Y.Ma Y.M.Ma F.E.Maas M.Maggiora S.Maldaner S.Malde Q.A.Malik A.Mangoni Y.J.Mao Z.P.Mao S.Marcello Z.X.Meng J.G.Messchendorp G.Mezzadri J.Min T.J.Min R.E.Mitchell X.H.Mo Y.J.Mo C.Morales Morales N.Yu.Muchnoi H.Muramatsu A.Mustafa S.Nakhoul Y.Nefedov F.Nerling I.B.Nikolaev Z.Ning S.Nisar S.L.Niu S.L.Olsen Q.Ouyang S.Pacetti Y.Pan M.Papenbrock P.Patteri M.Pelizaeus H.P.Peng K.Peters A.A.Petrov J.Pettersson J.L.Ping R.G.Ping A.Pitka R.Poling V.Prasad M.Qi T.Y.Qi S.Qian C.F.Qiao N.Qin X.P.Qin X.S.Qin Z.H.Qin J.F.Qiu S.Q.Qu K.H.Rashid C.F.Redmer M.Richter M.Ripka A.Rivetti V.Rodin M.Rolo G.Rong J.L.Rosner Ch.Rosner M.Rump A.Sarantsev M.Savrie K.Schoenning W.Shan X.Y.Shan M.Shao C.P.Shen P.X.Shen X.Y.Shen H.Y.Sheng X.Shi X.D Shi J.J.Song Q.Q.Song X.Y.Song S.Sosio C.Sowa S.Spataro F.F.Sui G.X.Sun J.F.Sun L.Sun S.S.Sun X.H.Sun Y.J.Sun Y.K Sun Y.Z.Sun Z.J.Sun Z.T.Sun Y.T Tan C.J.Tang G.Y.Tang X.Tang V.Thoren B.Tsednee I.Uman B.Wang B.L.Wang C.W.Wang D.Y.Wang H.H.Wang K.Wang L.L.Wang L.S.Wang M.Wang M.Z.Wang Wang Meng P.L.Wang R.M.Wang W.P.Wang X.Wang X.F.Wang X.L.Wang Y.Wang Y.F.Wang Z.Wang Z.G.Wang Z.Y.Wang Zongyuan Wang T.Weber D.H.Wei P.Weidenkaff H.W.Wen S.P.Wen U.Wiedner G.Wilkinson M.Wolke L.H.Wu L.J.Wu Z.Wu L.Xia Y.Xia S.Y.Xiao Y.J.Xiao Z.J.Xiao Y.G.Xie Y.H.Xie T.Y.Xing X.A.Xiong Q.L.Xiu G.F.Xu L.Xu Q.J.Xu W.Xu X.P.Xu F.Yan L.Yan W.B.Yan W.C.Yan Y.H.Yan H.J.Yang H.X.Yang L.Yang R.X.Yang S.L.Yang Y.H.Yang Y.X.Yang Yifan Yang Z.Q.Yang M.Ye M.H.Ye J.H.Yin Z.Y.You B.X.Yu C.X.Yu J.S.Yu C.Z.Yuan X.Q.Yuan Y.Yuan A.Yuncu A.A.Zafar Y.Zeng B.X.Zhang B.Y.Zhang C.C.Zhang D.H.Zhang H.H.Zhang H.Y.Zhang J.Zhang J.L.Zhang J.Q.Zhang J.W.Zhang J.Y.Zhang J.Z.Zhang K.Zhang L.Zhang S.F.Zhang T.J.Zhang X.Y.Zhang Y.Zhang Y.H.Zhang Y.T.Zhang Yang Zhang Yao Zhang Yi Zhang Yu Zhang Z.H.Zhang Z.P.Zhang Z.Q.Zhang Z.Y.Zhang G.Zhao J.W.Zhao J.Y.Zhao J.Z.Zhao Lei Zhao Ling Zhao M.G.Zhao Q.Zhao S.J.Zhao T.C.Zhao Y.B.Zhao Z.G.Zhao A.Zhemchugov B.Zheng J.P.Zheng Y.Zheng Y.H.Zheng B.Zhong L.Zhou L.P.Zhou Q.Zhou X.Zhou X.K.Zhou Xingyu Zhou Xiaoyu Zhou Xu Zhou A.N.Zhu J.Zhu J.Zhu K.Zhu K.J.Zhu S.H.Zhu W.J.Zhu X.L.Zhu Y.C.Zhu Y.S.Zhu Z.A.Zhu J.Zhuang B.S.Zou J.H.Zou 无 | 2020 | Chinese Physics C2020，44，4： | 517 |
| 5 | A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV) infected pneumonia(standard version)显示文摘In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province;and then named '2019 novel coronavirus(2019-nCoV)' by the World Health Organization(WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development;we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control(including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV. | Ying-Hui Jin Lin Cai Zhen-Shun Cheng Hong Cheng Tong Deng Yi-Pin Fan Cheng Fang Di Huang Lu-Qi Huang Qiao Huang Yong Han Bo Hu Fen Hu Bing-Hui Li Yi-Rong Li Ke Liang Li-Kai Lin Li-Sha Luo Jing Ma Lin-Lu Ma Zhi-Yong Peng Yun-Bao Pan Zhen-Yu Pan Xue-Qun Ren Hui-Min Sun Ying Wang Yun-Yun Wang Hong Weng Chao-Jie Wei Dong-Fang Wu Jian Xia Yong Xiong Hai-Bo Xu Xiao-Mei Yao Yu-Feng Yuan Tai-Sheng Ye Xiao-Chun Zhang Ying-Wen Zhang Yin-Gao Zhang Hua-Min Zhang Yan Zhao Ming-Juan Zhao Hao Zi Xian-Tao Zeng Yong-Yan Wang Xing-Huan Wang 无 | 2020 | Military Medical Research2020，7，1： | 161 |
| 6 | MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2显示文摘新兴的证据与肿瘤开发和前进显示出异常地表示的 microRNAs (miRNAs ) 的协会。然而,很少在胃的 carcinogenesis 对 miRNAs 的潜在的角色被知道。这里,我们执行了 miRNA microarray 屏蔽在配对的胃的癌症和他们的邻近的 nontumor 纸巾表示并且发现 miR-375 是的 miRNAs 差别极大地在胃的癌症纸巾的 downregulated。量的即时 PCR 分析证实那 miR-375 表情显著地从经历胃的切除术的病人与他们的 nontumor 对应物相比在超过 90% 主要胃的癌症被减少。miR-375 的 Overexpression 显著地在 vitro 并且在 vivo 禁止了胃的癌症房间增长。在胃的癌症房间的 miR-375 的强迫的表示显著地减少了 Janus kinase 的蛋白质水平 2 ( JAK2 )并且镇压带 JAK2 的 3 鈥? untranslated 区域的一个酶记者的活动,被预言的 miR-375-binding 地点的变化废除,显示那 JAK2 可以是 miR-375 目标基因。由由 RNAi 的 JAK2 的 AG490 或 silencing 的 JAK2 活动的任何一个抑制压制了类似于 miR-375 overexpression 的胃的癌症房间增长。而且, JAK2 的宫外的表示能部分颠倒 miR-375 引起的房间增长的抑制。最后,我们在胃的癌症发现了在 miR-375 表示和 JAK2 蛋白质水平之间的重要反的关联。因此,这些数据建议 miR-375 可以作为肿瘤 suppressor 工作由指向 JAK2 oncogene 潜在地调整胃的癌症房间增长,含有在胃的癌症的致病的 miR-375 的一个角色。 | Ling Ding Yanjun Xu Wei Zhang Yujie Deng Misi Si Ying Du Haomi Yao Xuyan Liu Yuehai Ke Jianmin Si Tianhua Zhou | 2010 | Cell Research2010，20，7： | 59 |
| 7 | LATERAL ORGAN BOUNDARIES DOMAIN transcription factors direct callus formation in Arabidopsis regeneration显示文摘在文化条件下面的植物纸巾或机关的显著新生能力有 underlain 为十年的一个广泛的惯例。在在 vitro 新生的植物的起始的步经常包含一个 pluripotent 房间团的正式就职称为的胼胝,它被植物激素植物生长素驾驶并且经由一条根发展小径发生。然而,管理胼胝形成的关键分子仍然保持未知。这里,我们证明 Arabidopsis 侧面的机关边界域(LBD )/ASYMMETRIC 象 LEAVES2 一样(ASL ) 抄写因素涉及胼胝形成节目的控制。植物生长素反应因素(ARF ) 下游的四 LBD 基因, LBD16, LBD17, LBD18 和 LBD29,被导致胼胝的媒介(计算机输入缩微胶卷) 很快并且戏剧性地在多重机关导致。每在 Arabidopsis 的四 LBD 基因的宫外的表示是足够的没有外长的植物激素,触发自发的胼胝形成,而 LBD 功能的抑制禁止计算机输入缩微胶卷导致的胼胝形成。而且, LBD 触发的胼胝类似于由宫外地激活的根分裂组织基因和有效新生能力的特征由计算机输入缩微胶卷导致了那。这些调查结果在胼胝正式就职进程把 LBD 抄写因素定义为关键管理者,从而建立在发信号的植物生长素和植物新生程序之间的一个分子的连接。 | Mingzhu Fan Chongyi Xu Ke Xu Yuxin Hu | 2012 | Cell Research2012，22，7： | 42 |
| 8 | New vacuum solar telescope and observations with high resolution显示文摘The New Vacuum Solar Telescope(NVST) is a one meter vacuum solar telescope that aims to observe fine structures on the Sun. The main goals of NVST are high resolution imaging and spectral observations, including measurements of the solar magnetic field. NVST is the primary ground-based facility used by the Chinese solar research community in this solar cycle. It is located by Fuxian Lake in southwest China, where the seeing is good enough to perform high resolution observations. We first introduce the general conditions at the Fuxian Solar Observatory and the primary science cases of NVST. Then, the basic structures of this telescope and instruments are described in detail. Finally, some typical high resolution data of the solar photosphere and chromosphere are also shown. | Zhong Liu Jun Xu Bo-Zhong Gu Sen Wang Jian-Qi You Long-Xiang Shen Ru-Wei Lu Zhen-Yu Jin Lin-Fei Chen Ke Lou Zhi Li Guang-Qian Liu Zhi Xu Chang-Hui Rao Qi-Qian Hu Ru-Feng Li Hao-Wen Fu Feng Wang Men-Xian Bao Ming-Chan Wu Bo-Rong Zhang | 2014 | Research in Astronomy and Astrophysics2014，14，6： | 37 |
| 9 | Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth显示文摘 | Yuan Yin Xing Cai Xi Chen Hongwei Liang Yujing Zhang Jing Li Zuoyun Wang Xiulan Chen Wen Zhang Seiji Yokoyama Cheng Wang Liang Li Limin Li Dongxia Hou Lei Dong Tao Xu Takachika Hiroi Fuquan Yang Hongbin Ji Junfeng Zhang Ke Zen Chen-Yu Zhang | 2014 | Cell Research2014，24，10： | 33 |
| 10 | Effects of nitrogen level on yield and quality of japonica soft super rice显示文摘Although studies on the balance between yield and quality of japonica soft super rice are limited, they are crucial for super rice cultivation. In order to investigate the effects of nitrogen application rate on grain yield and rice quality, two japonica soft super rice varieties, Nanjing 9108(NJ 9108) and Nanjing 5055(NJ 5055), were used under seven N levels with the application rates of 0, 150, 187.5, 225, 262.5, 300, and 337.5 kg ha^(–1). With the increasing nitrogen application level, grain yield of both varieties first increased and then decreased. The highest yield was obtained at 300 kg ha^(–1). The milling quality and protein content increased, while the appearance quality, amylose content, gel consistency, cooking/eating quality, and rice flour viscosity decreased. Milling was significantly negatively related with the eating/cooking quality whereas the appearance was significantly positively related with cooking/eating quality. These results suggest that nitrogen level significantly affects the yield and rice quality of japonica soft super rice. We conclude that the suitable nitrogen application rate for japonica soft super rice, NJ 9108 and NJ 5055, is 270 kg ha^(–1), under which they obtain high yield as well as superior eating/cooking quality. | ZHU Da-wei ZHANG Hong-cheng GUO Bao-wei XU Ke DAI Qi-gen WEI Hai-yan GAO Hui HU Ya-jie CUI Pei-yuan HUO Zhong-yang | 2017 | Journal of Integrative Agriculture2017，16，5： | 31 |
| 11 | Natural Variation in the Promoter of GSE5 Contributes to Grain Size Diversity in Rice显示文摘自然基因变化的利用极大地在庄稼贡献重要农学的特点的改进。为谷物尺寸的自然变化理解基因基础能帮助 breeders 开发产量很高的米饭变化。在这研究,我们识别以前未被认出的基因,命名 GSE5,与功能的分析在由联合染色体宽的协会控制米饭谷物尺寸的 qSW5/GW5 地点学习。GSE5 编码血浆有 IQ 领域的联系膜的蛋白质,与米饭 calmodulin 蛋白质交往, OsCaM1-1。我们发现 GSE5 功能的损失引起了宽、重的谷物,当 GSE5 的 overexpression 导致了狭窄的谷物时。我们证明 GSE5 由在小穗状花小穗壳影响房间增长主要调整谷物尺寸。GSE5 的三主要 haplotypes (GSE5, GSE5 DEL1+IN1 , 和 GSE5 在栽培米饭的 DEL2 ) 在它的倡导者区域基于删除 / 插入类型被识别。我们表明了那在带 GSE5 在带 GSE5 haplotype 和 1212-bp 删除(DEL2 )> 与 GSE5 的减少的表示联系的 DEL2 haplotype,导致宽谷物。进一步的分析显示野米饭就职包含 GSE5 的所有三 haplotypes,建议在栽培米饭在场的 GSE5 haplotypes 是可能的从在米饭驯服期间的不同野米饭就职发源。一起拿,我们的结果显示在 qSW5/GW5 地点的以前未被认出的 GSE5 基因,被米饭 breeders 广泛地利用,控制谷物缩放,并且表明在 GSE5 的倡导者区域的那个自然变化在米饭贡献谷物尺寸差异。 | Penggen Duan Jinsong Xu Dali Zeng Baolan Zhang Mufan Geng Guozheng Zhang Ke Huang Luojiang Huang Ran Xu Song Ge Qian Qian Yunhai Li | 2017 | Molecular Plant2017，10，5： | 31 |
| 12 | Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients显示文摘Human infection with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)causes coronavirus disease 2019(COVID-19)and there is no cure currently.The 3CL protease(3CLpro)is a highly conserved protease which is indispensable for CoVs replication,and is a promising target for development of broad-spectrum antiviral drugs.In this study we investigated the anti-SARS-CoV-2 potential of Shuanghuanglian preparation,a Chinese traditional patent medicine with a long history for treating respiratory tract infection in China.We showed that either the oral liquid of Shuanghuanglian,the lyophilized powder of Shuanghuanglian for injection or their bioactive components dose-dependently inhibited SARS-CoV-23CLpro as well as the replication of SARS-CoV-2 in Vero E6 cells.Baicalin and baicalein,two ingredients of Shuanghuanglian,were characterized as the first noncovalent,nonpeptidomimetic inhibitors of SARS-CoV-23CLpro and exhibited potent antiviral activities in a cell-based system.Remarkably,the binding mode of baicalein with SARS-CoV-23CLpro determined by X-ray protein crystallography was distinctly different from those of known 3CLpro inhibitors.Baicalein was productively ensconced in the core of the substrate-binding pocket by interacting with two catalytic residues,the crucial S1/S2 subsites and the oxyanion loop,acting as a“shield”in front of the catalytic dyad to effectively prevent substrate access to the catalytic dyad within the active site.Overall,this study provides an example for exploring the in vitro potency of Chinese traditional patent medicines and effectively identifying bioactive ingredients toward a specific target,and gains evidence supporting the in vivo studies of Shuanghuanglian oral liquid as well as two natural products for COVID-19 treatment. | Hai-xia Su Sheng Yao Wen-feng Zhao Min-jun Li Jia Liu Wei-juan Shang Hang Xie Chang-qiang Ke Hang-chen Hu Mei-na Gao Kun-qian Yu Hong Liu Jing-shan Shen Wei Tang Lei-ke Zhang Geng-fu Xiao Li Ni Dao-wen Wang Jian-ping Zuo Hua-liang Jiang Fang Bai Yan Wu Yang Ye Ye-chun Xu | 2020 | Acta Pharmacologica Sinica2020，41，9： | 32 |
| 13 | Study of BESIII trigger efficiencies with the 2018 J/ψ data显示文摘Using a dedicated data sample taken in 2018 on the J/ψpeak,we perform a detailed study of the trigger efficiencies of the BESIII detector.The efficiencies are determined from three representative physics processes,namely Bhabha scattering,dimuon production and generic hadronic events with charged particles.The combined efficiency of all active triggers approaches 100%in most cases,with uncertainties small enough not to affect most physics analyses. | M.Ablikim M.N.Achasov P.Adlarson S.Ahmed M.Albrecht R.Aliberti A.Amoroso M.R.An Q.An X.H.Bai Y.Bai O.Bakina R.Baldini Ferroli I.Balossino Y.Ban K.Begzsuren N.Berger M.Bertani D.Bettoni F.Bianchi J.Bloms A.Bortone I.Boyko R.A.Briere H.Cai X.Cai A.Calcaterra G.F.Cao N.Cao S.A.Cetin J.F.Chang W.L.Chang G.Chelkov D.Y.Chen G.Chen H.S.Chen M.L.Chen S.J.Chen X.R.Chen Y.B.Chen Z.J Chen W.S.Cheng G.Cibinetto F.Cossio X.F.Cui H.L.Dai X.C.Dai A.Dbeyssi R.E.de Boer D.Dedovich Z.Y.Deng A.Denig I.Denysenko M.Destefanis F.De Mori Y.Ding C.Dong J.Dong L.Y.Dong M.Y.Dong X.Dong S.X.Du Y.L.Fan J.Fang S.S.Fang Y.Fang R.Farinelli L.Fava F.Feldbauer G.Felici C.Q.Feng J.H.Feng M.Fritsch C.D.Fu Y.Gao Y.Gao Y.Gao Y.G.Gao I.Garzia P.T.Ge C.Geng E.M.Gersabeck A Gilman K.Goetzen L.Gong W.X.Gong W.Gradl M.Greco L.M.Gu M.H.Gu S.Gu Y.T.Gu C.Y Guan A.Q.Guo L.B.Guo R.P.Guo Y.P.Guo A.Guskov T.T.Han W.Y.Han X.Q.Hao F.A.Harris H Hüsken K.L.He F.H.Heinsius C.H.Heinz T.Held Y.K.Heng C.Herold M.Himmelreich T.Holtmann Y.R.Hou Z.L.Hou H.M.Hu J.F.Hu T.Hu Y.Hu G.S.Huang L.Q.Huang X.T.Huang Y.P.Huang Z.Huang T.Hussain W.Ikegami Andersson W.Imoehl M.Irshad S.Jaeger S.Janchiv Q.Ji Q.P.Ji X.B.Ji X.L.Ji H.B.Jiang X.S.Jiang J.B.Jiao Z.Jiao S.Jin Y.Jin T.Johansson N.Kalantar-Nayestanaki X.S.Kang R.Kappert M.Kavatsyuk B.C.Ke I.K.Keshk A.Khoukaz P.Kiese R.Kiuchi R.Kliemt L.Koch O.B.Kolcu B.Kopf M.Kuemmel M.Kuessner A.Kupsc M.G.Kurth W.Kühn J.J.Lane J.S.Lange P.Larin A.Lavania L.Lavezzi Z.H.Lei H.Leithoff M.Lellmann T.Lenz C.Li C.H.Li Cheng Li D.M.Li F.Li G.Li H.Li H.Li H.B.Li H.J.Li J.L.Li J.Q.Li J.S.Li Ke Li L.K.Li Lei Li P.R.Li S.Y.Li W.D.Li W.G.Li X.H.Li X.L.Li Z.Y.Li H.Liang H.Liang H.Liang Y.F.Liang Y.T.Liang L.Z.Liao J.Libby C.X.Lin B.J.Liu C.X.Liu D.Liu F.H.Liu Fang Liu Feng Liu H.B.Liu H.M.Liu Huanhuan Liu Huihui Liu J.B.Liu J.L.Liu J.Y.Liu K.Liu K.Y.Liu Ke Liu L.Liu M.H.Liu P.L.Liu Q.Liu Q.Liu S.B.Liu Shuai Liu T.Liu W.M.Liu X.Liu Y.Liu Y.B.Liu Z.A.Liu Z.Q.Liu X.C.Lou F.X.Lu H.J.Lu J.D.Lu J.G.Lu X.L.Lu Y.Lu Y.P.Lu C.L.Luo M.X.Luo b P.W.Luo T.Luo X.L.Luo S.Lusso X.R.Lyu F.C.Ma H.L.Ma L.L.Ma M.M.Ma Q.M.Ma R.Q.Ma R.T.Ma X.X.Ma X.Y.Ma F.E.Maas M.Maggiora S.Maldaner S.Malde Q.A.Malik A.Mangoni Y.J.Mao Z.P.Mao S.Marcello Z.X.Meng J.G.Messchendorp G.Mezzadri T.J.Min R.E.Mitchell X.H.Mo Y.J.Mo N.Yu.Muchnoi H.Muramatsu S.Nakhoul Y.Nefedov F.Nerling I.B.Nikolaev Z.Ning S.Nisar S.L.Olsen Q.Ouyang S.Pacetti X.Pan Y.Pan A.Pathak P.Patteri M.Pelizaeus H.P.Peng K.Peters J.Pettersson J.L.Ping R.G.Ping R.Poling V.Prasad H.Qi H.R.Qi K.H.Qi M.Qi T.Y.Qi T.Y.Qi S.Qian W.-B.Qian Z.Qian C.F.Qiao L.Q.Qin X.S.Qin Z.H.Qin J.F.Qiu S.Q.Qu K.H.Rashid K.Ravindran C.F.Redmer A.Rivetti V.Rodin M.Rolo G.Rong Ch.Rosner M.Rump H.S.Sang A.Sarantsev Y.Schelhaas C.Schnier K.Schoenning M.Scodeggio D.C.Shan W.Shan X.Y.Shan J.F.Shangguan M.Shao C.P.Shen P.X.Shen X.Y.Shen H.C.Shi R.S.Shi X.Shi X.D Shi W.M.Song Y.X.Song S.Sosio S.Spataro K.X.Su P.P.Su F.F.Sui G.X.Sun H.K.Sun J.F.Sun L.Sun S.S.Sun T.Sun W.Y.Sun X Sun Y.J.Sun Y.K.Sun Y.Z.Sun Z.T.Sun Y.H.Tan Y.X.Tan C.J.Tang G.Y.Tang J.Tang J.X.Teng V.Thoren I.Uman B.Wang C.W.Wang D.Y.Wang H.J.Wang H.P.Wang K.Wang L.L.Wang M.Wang M.Z.Wang Meng Wang W.Wang W.H.Wang W.P.Wang X.Wang X.F.Wang X.L.Wang Y.Wang Y.D.Wang Y.F.Wang Y.Q.Wang Y.Y.Wang Z.Wang Z.Y.Wang Ziyi Wang Zongyuan Wang D.H.Wei P.Weidenkaff F.Weidner S.P.Wen D.J.White U.Wiedner G.Wilkinson M.Wolke L.Wollenberg J.F.Wu L.H.Wu L.J.Wu X.Wu Z.Wu L.Xia H.Xiao S.Y.Xiao Z.J.Xiao X.H.Xie Y.G.Xie Y.H.Xie T.Y.Xing G.F.Xu Q.J.Xu W.Xu X.P.Xu F.Yan L.Yan W.B.Yan W.C.Yan Xu Yan H.J.Yang H.X.Yang L.Yang S.L.Yang Y.X.Yang Yifan Yang Zhi Yang M.Ye M.H.Ye J.H.Yin Z.Y.You B.X.Yu C.X.Yu G.Yu J.S.Yu T.Yu C.Z.Yuan L.Yuan X.Q.Yuan Y.Yuan Z.Y.Yuan C.X.Yue A.Yuncu A.A.Zafar Y.Zeng B.X.Zhang Guangyi Zhang H.Zhang H.H.Zhang H.Y.Zhang J.J.Zhang J.L.Zhang J.Q.Zhang J.W.Zhang J.Y.Zhang J.Z.Zhang Jianyu Zhang Jiawei Zhang L.Q.Zhang Lei Zhang S.Zhang S.F.Zhang Shulei Zhang X.D.Zhang X.Y.Zhang Y.Zhang Y.H.Zhang Y.T.Zhang Yan Zhang Yao Zhang Yi Zhang Z.H.Zhang Z.Y.Zhang G.Zhao J.Zhao J.Y.Zhao J.Z.Zhao Lei Zhao Ling Zhao M.G.Zhao Q.Zhao S.J.Zhao Y.B.Zhao Y.X.Zhao Z.G.Zhao A.Zhemchugov B.Zheng J.P.Zheng Y.Zheng Y.H.Zheng B.Zhong C.Zhong L.P.Zhou Q.Zhou X.Zhou X.K.Zhou X.R.Zhou A.N.Zhu J.Zhu K.Zhu K.J.Zhu S.H.Zhu T.J.Zhu W.J.Zhu W.J.Zhu Y.C.Zhu Z.A.Zhu B.S.Zou J.H.Zou | 2021 | Chinese Physics C2021，45，2： | 33 |
| 14 | A national report from China Liver Transplant Registry: steroid avoidance after liver transplantation for hepatocellular carcinoma显示文摘Objective:We aimed to evaluate the efficacy and safety of steroid-free immunosuppression after liver transplantation(LT)for hepatocellular carcinoma(HCC).Methods:We retrospectively analyzed HCC recipients without steroids after LT(SF group,n=368)based on the China Liver Transplant Registry(CLTR)database.These recipients were matched 1:2 with patients using steroids(S group,n=736)for the same period after LT for HCC,according to propensity scores.Results:Multivariate analysis indicates that recipients with younger age[odds ratio(OR),1.053;P=0.011],preoperative hepatitis B virus(HBV)DNA≥1,000 copies/mL(OR,2.597;P=0.004)and beyond Milan criteria(OR,4.255;P<0.001)were identified as the risk factors associated with tumor recurrence in steroid avoidance recipients after LT.The patients fulfilling the Milan criteria in the SF group presented higher overall and tumor-free survival rates than those in the S group(P<0.05).Multivariate analysis revealed that recipient beyond Milan criteria was an independent prognostic factor for overall survival(OR,1.690;P<0.001)and tumor-free survival(OR,2.066;P<0.001).The incidences of new-onset diabetes mellitus(21.20% vs.33.29%,P<0.001),new-onset hypertension(10.05%vs.18.61%,P<0.001)and hyperlipidemia(4.08% vs.7.20%,P=0.042)were significantly lower in the SF group.Conclusions:Steroid-free immunosuppression could be safe and feasible for HBV-related HCC patients in LT.Age,HBV DNA level and Milan criteria maybe risk factors associated with tumor recurrence in steroid avoidance recipients.Recipient beyond Milan criteria was an independent prognostic factor and recipient fulfilling Milan criteria can benefit the most from steroid-free immunosuppression. | Qiang Wei Feng Gao Runzhou Zhuang Qi Ling Qinghong Ke Jian Wu Tian Shen Mangli Zhang Min Zhang Xiao Xu Shusen Zheng | 2017 | Chinese Journal of Cancer Research2017，29，5： | 25 |
| 15 | Decreased expression of human aquaporin-5 correlated with mucus overproduction in airways of chronic obstructive pulmonary disease显示文摘目的:调查在 aquaporin-5 ( AQP5 )之间的关系在有长期的妨碍的肺的疾病( COPD )和与肺的功能 change.Methods 的关联的中国病人的航线的表示和粘液生产过剩:支气管的纸巾从纤维被获得到 July2004.Twenty 的从4月的韦斯特中国医院里的眼的 bronchoscopy 和支气管的活体检视--五病人们作为 COPD 病人,和另外一个被诊断 20 作为控制病人被诊断。 AQP5 ,粘蛋白 5AC ( MUC5AC ),和在支气管的纸巾的粘蛋白的表情被半检测量的 RT-PCR 在 situ 杂交,和组织化学的免疫和染色的alcianblue周期的 acid-Schiff (AB舞步), respectively.Results :与控制组相比, AQP5 的稀释表情从病人 withCOPD 在整个支气管的纸巾被检测( P < 0.01 ),但是没有差别在肺纸巾存在( P > 0.05 )。同时,增加了 MUC5AC 染色,在 submucosal 腺的粘液被注意(P < 0.01,分别地) 。吸烟稀释了 AQP5 的表情并且增加了在 COPDgroups 在 submucosal 腺染色 MUC5AC 和粘液( P < 0.01 ),当有时,没有重要差别在控制组观察了( P > 0.05 ) AQP5 mRNA 的 .Thedecreased 表示在 1 s ( FEV1 )与强迫的吐气的体积被相关 /forcedvital 能力( FVC )( r=0.60 , P < 0.01 ),FEV1%预言了值( r=0.60 , P < 0.01 ),重要能力( V50 )%预言了的最大的吐气的流动in50%值( r=0.55 , P < 0.01 ),并且在25%重要能力( V25 )的最大的吐气的流动%预言了值( r=0,45 , P < 0.01 )。减少的表达式否定地与上皮航线的 MUC5AC mRNA 被相关(r=-0.45, P < 0.01 ) 并且 submucosalglands 的 AB-PAS-stained 区域(r=-0.61, P < 0.01 ) 。起来 MUC5AC mRNA 的规定相关与断然 submucosal 腺的 AB-PAS-stainedarea 并且与 FEV1/FVC 否定地相关( r=-0.53 ; P < 0.01 ),FEV1%预言了值( r=-0.53 ; P < 0.01 ),V50%预言了值( r=-0.48 ; P < 0.01 ),并且V25%预言了值( r=-0.43 ; P < 0.01 ) .Conclusion : AQP5 的稀释基因表达式在中国 COPD 病人的航线存在,它由粘液分泌过盛是复杂的。AQP5mRNA 的减少的表达式可能与气流阻塞的严厉有关。 | Ke WANG Yu-lin FENG Fu-qiang WEN Xue-rong CHEN Xue-mei OU Dan XU Jie YANG Zhi-ping DENG | 2007 | Acta Pharmacologica Sinica2007，28，8： | 24 |
| 16 | Antibacterial Mechanism of Copper-bearing Antibacterial Stainless Steel against E.Coli显示文摘初步的研究通过象 EDTA (ethylenediaminetetraacetic 酸) 那样的微生物学的实验对 E.coli 在忍受铜的抗菌剂不锈钢的抗菌剂机制上被做 complex-ing, DNA 涂和 AFM (原子力量显微镜) 观察。抗菌剂不锈钢在 99.99%.The 抗菌剂率上与抗菌剂率显示出优秀抗菌剂功能到 E.coli,这被测量如果细菌答案是由 EDTA 的 complexed,是弱的,显示铜离子在抗菌剂不锈钢的抗菌剂效果起一个主导的作用。电气泳动实验没显示出在联系抗菌剂不锈钢以后为 E.coli 涂的 DNA 的现象,它意味着 E.coli 的那 DNA 显然没被损坏。E.coli 的形态学在联系抗菌剂不锈钢以后改变了很多,这被 AFM 观察,例如房间墙严重被改变,在房间的大量内容正在被漏。 | Li NAN Weichao YANG Yongqian LIU Hui XU Ying LI Manqi LU Ke YANG | 2008 | Journal of Materials Science & Technology2008，24，2： | 24 |
| 17 | Systematic review and meta-analysis of laparoscopy-assisted and open total gastrectomy for gastric cancer显示文摘AIM:To evaluate the safety and efficacy of laparoscopy-assisted total gastrectomy(LATG)and open total gastrectomy(OTG)for gastric cancer.METHODS:A comprehensive search of PubMed,Cochrane Library,Web of Science and BIOSIS Previews was performed to identify studies that compared LATG and OTG.The following factors were checked:operating time,blood loss,harvested lymph nodes,flatus time,hospital stay,mortality and morbidity.Data synthesis and statistical analysis were carried out using RevMan 5.1 software.RESULTS:Nine studies with 1221 participants were included(436 LATG and 785 OTG).Compared to OTG,LATG involved a longer operating time[weighted mean difference(WMD)=57.68 min,95%CI:30.48-84.88;P<0.001];less blood loss[standard mean difference(SMD)=-1.71;95%CI:-2.48--0.49;P<0.001];earlier time to flatus(WMD=-0.76 d;95%CI:-1.22--0.30;P<0.001);shorter hospital stay(WMD=-2.67d;95%CI:-3.96--1.38,P<0.001);and a decrease in medical complications(RR=0.41,95%CI:0.19-0.90,P=0.03).The number of harvested lymph nodes,mortality,surgical complications,cancer recurrence rate and long-term survival rate of patients undergoing LATG were similar to those in patients undergoing OTG.CONCLUSION:Despite a longer operation,LATG can be performed safely in experienced surgical centers with a shorter hospital stay and fewer complications than open surgery. | Ke Chen Xiao-Wu Xu Ren-Chao Zhang Yu Pan Di Wu Yi-Ping Mou | 2013 | World Journal of Gastroenterology2013，19，32： | 23 |
| 18 | Laparoscopic distal pancreatectomy is as safe and feasible as open procedure:A meta-analysis显示文摘AIM:To evaluate the feasibility and safety of laparoscopic distal pancreatectomy(LDP) compared with open distal pancreatectomy(ODP).METHODS:Meta-analysis was performed using the databases,including PubMed,the Cochrane Central Register of Controlled Trials,Web of Science and BIOSIS Previews.Articles should contain quantitative data of the comparison of LDP and ODP.Each article was reviewed by two authors.Indices of operative time,spleen-preserving rate,time to fluid intake,ratio of malignant tumors,postoperative hospital stay,incidence rate of pancreatic fistula and overall morbidity rate were analyzed.RESULTS:Nine articles with 1341 patients who underwent pancreatectomy met the inclusion criteria.LDP was performed in 501(37.4%) patients,while ODP was performed in 840(62.6%) patients.There were significant differences in the operative time,time to fluid intake,postoperative hospital stay and spleen-preserving rate between LDP and ODP.There was no difference between the two groups in pancreatic fistula rate [random effects model,risk ratio(RR) 0.996(0.663,1.494),P = 0.983,I2 = 28.4%] and overall morbidity rate [random effects model,RR 0.81(0.596,1.101),P = 0.178,I2 = 55.6%].CONCLUSION:LDP has the advantages of shorter hospital stay and operative time,more rapid recovery and higher spleen-preserving rate as compared with ODP. | Kun Xie Yi-Ping Zhu Xiao-Wu Xu Ke Chen Jia-Fei Yan Yi-Ping Mou | 2012 | World Journal of Gastroenterology2012，18，16： | 22 |
| 19 | Deep carbon cycles constrained by a large-scale mantle Mg isotope anomaly in eastern China显示文摘Although deep carbon recycling plays an important role in the atmospheric CO_2 budget and climate changes through geological time,the precise mechanisms remain poorly understood.Since recycled sedimentary carbonate through plate subduction is the main light-δ^(26)Mg reservoir within deep-Earth,Mg isotope variation in mantle-derived melts provides a novel perspective when investigating deep carbon cycling.Here,we show that the Late Cretaceous and Cenozoic continental basalts from 13 regions covering the whole of eastern China have low δ^(26)Mg isotopic compositions,while the Early Cretaceous basalts from the same area and the island arc basalts from circum-Paciic subduction zones have mantle-like or heavy Mg isotopic characteristics.hus,a large-scale mantle low δ^(26)Mg anomaly in eastern China has been delineated,suggesting the contribution of sedimentary carbonates recycled into the upper mantle,but limited into the lower mantle.his large-scale spatial and temporal variation of Mg isotopes in the mantle places severe constraints on deep carbon recycling via oceanic subduction. | Shu-Guang Li Wei Yang Shah Ke Xunan Meng Hengci Tian Lijuan Xu Yongsheng He Jian Huang Xuan-Ce Wang Qunke Xia Weidong Sun Xiaoyong Yang Zhong-Yuan Ren Haiquan Wei Yongsheng Liu Fancong Meng Jun Yan | 2017 | National Science Review2017，4，1： | 23 |
| 20 | Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy显示文摘Locoregional therapies(LRTs)of hepatocellular carcinoma(HCC)represented by ablation and TACE has become the main means for the clinical treatment of unresectable HCC.Among these,TACE is used throughout the stageⅠb toⅢb of HCC treatment.In recent years,immunotherapy led by immune checkpoint inhibitors has become a hot direction in clinical research.At the same time,targeted drugs such as Sorafenib and Apatinib have played an important role in the treatment and complementary therapy of advanced HCC,and their clinical application has been quite mature.HCC is the sixth most common malignant tumor in the world.When it comes to its treatment,different therapies have different indications,and their individual efficacies are not satisfactory,which makes the exploration of the use of combination therapy in HCC treatment become a new trend.In this paper,the status of the three therapies and the progress of their combined application are briefly reviewed. | Jian Xue Hongbo Ni Fan Wang Ke Xu Meng Niu | 2021 | Journal of Interventional Medicine2021，4，3： | 21 |
您所在的机构暂未开通此部分的功能，请联系管理员